Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
Lei Xu, Emmanuelle di Tomaso(Bayer (United States)), Dan G. Duda(Harvard University), Gregory Y. Lauwers(Moffitt Cancer Center), Paul C. Shellito(Harvard University), Marek Ancukiewicz(Bridge University), Martin Poleski(Duke Medical Center), Brian G. Czito(Harvard University), Pei‐Chun Lin, Rex C. Bentley(Duke University), Jeffrey W. Clark(Massachusetts General Hospital), Daniel C. Chung(Penn Presbyterian Medical Center), Christopher G. Willett, Rekha Samuel
Cited by 161
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k